Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | GRB2 | P62993 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415321 | 1.00 | LCK (0.55) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL1575213 | 0.88 | LCK (0.71) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL14827224 | 0.87 | ALDH1A1 (0.56) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL723839 | 0.85 | LCK (0.76) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL7115912 | 0.84 | LCK (0.54) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL14454704 | 0.83 | CA12 (0.52) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL7919717 | 0.83 | KDM4E (0.74) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL27850010 | 0.83 | CA12 (0.58) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL4211621 | 0.81 | NQO1 (0.54) | LCKAKR1B1FYNGRB2KDM4E | |
| SCHEMBL7037768 | 0.81 | HSD17B3 (0.51) | LCKAKR1B1FYNGRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075734-A | Conjugates comprising tetrapeptides, methods of making, intermediates and uses thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | claimed |
| US-20250223627-A1 | FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS | Sunbird Bio, Inc. | 2025-07-10 | — | — | US | claimed |
| US-20250215476-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR HEPATOCELLULAR CARCINOMA | Sunbird Bio, Inc. | 2025-07-03 | — | — | US | claimed |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| US-12305217-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-05-20 | — | — | US | claimed |
| US-20250110130-A1 | EX VIVO PROTEASE ACTIVATION AND DETECTION | Sunbird Bio, Inc. | 2025-04-03 | — | — | US | claimed |
| US-20250092437-A1 | DISEASE DETECTION WITH COMBINATORIAL BIOMARKERS | Sunbird Bio, Inc. | 2025-03-20 | — | — | US | claimed |
| EP-4500186-A2 | EX VIVO PROTEASE ACTIVITY DETECTION FOR HEPATOCELLULAR CARCINOMA | Sunbird Bio, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| WO-2025019414-A1 | SUBSTRATE-BASED PROBES FOR MONITORING PROTEASE ACTIVITY USING MALDI-TOFMS | ZETEO TECH, INC. (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2005023835-A2 | MODULATORS OF TRANSMEMBRANE PROTEASE SERINE 6 | IRM LLC (BM) | 2005-03-17 | — | — | WO | claimed |
| US-20050054027-A1 | Modulators of transmembrane protease serine 6 | IRM LLC (BM) | 2005-03-10 | — | — | US | claimed |
| WO-2005007663-A2 | FLUOROGENIC ENZYME SUBSTRATES AND USES THEREOF | IRM LLC (BM) | 2005-01-27 | — | — | WO | claimed |
| US-6797461-B2 | Tryptase substrates and assay for tryptase activity using same | PROMEGA CORPORATION | 2004-09-28 | — | — | US | claimed |
| WO-2002034765-A9 | us0130034IDIC TRYPTASE SUBSTRATES AND ASSAY FOR TRYPTASE ACTIVITY USING SAME | PROMEGA CORP (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1358205-A2 | TETRAPEPTIDIC TRYPTASE SUBSTRATES AND ASSAY FOR TRYPTASE ACTIVITY USING SAME | PROMEGA CORPORATION (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | claimed |
| US-20030059847-A1 | Combinatorial protease substrate libraries | IRM, LLC (BM) | 2003-03-27 | — | — | US | claimed |
| US-20020197661-A1 | Tryptase substrates and assay for tryptase activity using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | claimed |
| WO-2002034765-A2 | us0130034IDIC TRYPTASE SUBSTRATES AND ASSAY FOR TRYPTASE ACTIVITY USING SAME | PROMEGA CORPORATION (US) | 2002-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | LCK 4562/4885AKR1B1 1703/4885FYN 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.